261 results on '"Creutzberg, Carien"'
Search Results
2. Sexual health—a topic for cancer patients receiving oncological treatment with palliative intent
- Author
-
Schmalz, Claudia, Oberguggenberger, Anne S., Nagele, Eva, Bliem, Brigitte, Lanceley, Anne, Nordin, Andy, Kuljanic, Karin, Jensen, Pernille T., Bjelic-Radisic, Vesna, Fabian, Alexander, Arraras, Juan I., Wei-Chu, Chie, Creutzberg, Carien L., Galalae, Razvan, Toelen, Hilde, Zimmermann, Kristin, Costantini, Anna, Almont, Thierry, Serpentini, Samantha, Frøding, Ligita Paskeviciute, Vistad, Ingvild, Tomaszewski, Krzysztof A., Inwald, Elisabeth, and Greimel, Elfriede
- Published
- 2024
- Full Text
- View/download PDF
3. Adaptive Objective Configuration in Bi-Objective Evolutionary Optimization for Cervical Cancer Brachytherapy Treatment Planning
- Author
-
Dickhoff, Leah R. M., Kerkhof, Ellen M., Deuzeman, Heloisa H., Creutzberg, Carien L., Alderliesten, Tanja, and Bosman, Peter A. N.
- Subjects
Computer Science - Neural and Evolutionary Computing - Abstract
The Multi-Objective Real-Valued Gene-pool Optimal Mixing Evolutionary Algorithm (MO-RV-GOMEA) has been proven effective and efficient in solving real-world problems. A prime example is optimizing treatment plans for prostate cancer brachytherapy, an internal form of radiation treatment, for which equally important clinical aims from a base protocol are grouped into two objectives and bi-objectively optimized. This use of MO-RV-GOMEA was recently successfully introduced into clinical practice. Brachytherapy can also play an important role in treating cervical cancer. However, using the same approach to optimize treatment plans often does not immediately lead to clinically desirable results. Concordantly, medical experts indicate that they use additional aims beyond the cervix base protocol. Moreover, these aims have different priorities and can be patient-specifically adjusted. For this reason, we propose a novel adaptive objective configuration method to use with MO-RV-GOMEA so that we can accommodate additional aims of this nature. Based on results using only the base protocol, in consultation with medical experts, we configured key additional aims. We show how, for 10 patient cases, the new approach achieves the intended result, properly taking into account the additional aims. Consequently, plans resulting from the new approach are preferred by medical specialists in 8/10 cases.
- Published
- 2022
4. Automated causal inference in application to randomized controlled clinical trials
- Author
-
Wu, Jiqing, Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C. H. W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T. H. B. M., Bosse, Tjalling, Creutzberg, Carien L., and Koelzer, Viktor H.
- Subjects
Statistics - Methodology ,Computer Science - Artificial Intelligence ,Computer Science - Machine Learning - Abstract
Randomized controlled trials (RCTs) are considered as the gold standard for testing causal hypotheses in the clinical domain. However, the investigation of prognostic variables of patient outcome in a hypothesized cause-effect route is not feasible using standard statistical methods. Here, we propose a new automated causal inference method (AutoCI) built upon the invariant causal prediction (ICP) framework for the causal re-interpretation of clinical trial data. Compared to existing methods, we show that the proposed AutoCI allows to efficiently determine the causal variables with a clear differentiation on two real-world RCTs of endometrial cancer patients with mature outcome and extensive clinicopathological and molecular data. This is achieved via suppressing the causal probability of non-causal variables by a wide margin. In ablation studies, we further demonstrate that the assignment of causal probabilities by AutoCI remain consistent in the presence of confounders. In conclusion, these results confirm the robustness and feasibility of AutoCI for future applications in real-world clinical analysis., Comment: Submitted to Nature Machine Intelligence. The code is publicly available via https://github.com/CTPLab/AutoCI
- Published
- 2022
5. Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
- Author
-
Oonk, Maaike HM, Slomovitz, Brian, Baldwin, Peter JW, van Doorn, Helena C, van der Velden, Jacobus, de Hullu, Joanne A, Gaarenstroom, Katja N, Slangen, Brigitte FM, Vergote, Ignace, Brännström, Mats, van Dorst, Eleonora BL, van Driel, Willemien J, Hermans, Ralph H, Nunns, David, Widschwendter, Martin, Nugent, David, Holland, Cathrine M, Sharma, Aarti, DiSilvestro, Paul A, Mannel, Robert, Boll, Dorry, Cibula, David, Covens, Al, Provencher, Diane, Runnebaum, Ingo B, Luesley, David, Ellis, Patricia, Duncan, Timothy J, Tjiong, Ming Y, Cruickshank, Derek J, Kjølhede, Preben, Levenback, Charles F, Bouda, Jiri, Kieser, Katharina E, Palle, Connie, Spirtos, Nicola M, O'Malley, David M, Leitao, Mario M, Geller, Melissa A, Dhar, Kalyan, Asher, Viren, Tamussino, Karl, Tobias, Daniel H, Borgfeldt, Christer, Lea, Jayanthi S, Bailey, Jo, Lood, Margareta, Eyjolfsdottir, Brynhildur, Attard-Montalto, Stephen, Tewari, Krishnansu S, Manchanda, Ranjit, Jensen, Pernille T, Persson, Par, Van Le, Linda, Putter, Hein, de Bock, Geertruida H, Monk, Bradley J, Creutzberg, Carien L, and van der Zee, Ate GJ
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Clinical Research ,Cancer ,Evaluation of treatments and therapeutic interventions ,6.5 Radiotherapy and other non-invasive therapies ,Aged ,Female ,Humans ,Lymph Node Excision ,Lymphatic Metastasis ,Middle Aged ,Neoplasm Micrometastasis ,Neoplasm Staging ,Prospective Studies ,Radiation Dosage ,Sentinel Lymph Node ,Time Factors ,Treatment Outcome ,Vulvar Neoplasms ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
PurposeThe Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN).MethodsGROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences.ResultsFrom December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL.ConclusionInguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
- Published
- 2021
6. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
- Author
-
Vermij, Lisa, Jobsen, Jan J., León-Castillo, Alicia, Brinkhuis, Mariel, Roothaan, Suzan, Powell, Melanie E., de Boer, Stephanie M., Khaw, Pearly, Mileshkin, Linda R., Fyles, Anthony, Leary, Alexandra, Genestie, Catherine, Jürgenliemk-Schulz, Ina M., Crosbie, Emma J., Mackay, Helen J., Nijman, Hans. W., Nout, Remi A., Smit, Vincent T. H. B. M., Creutzberg, Carien L., Horeweg, Nanda, and Bosse, Tjalling
- Published
- 2023
- Full Text
- View/download PDF
7. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27
- Author
-
Oerlemans, Simone, Efficace, Fabio, Shamieh, Omar, Cardoso Borges, Fabio, de Jong, Corine, Dong, Dong, Lehmann, Jens, Malak, Sandra, Petranovic, Duska, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Nagele, Eva, Bredart, Anne, Carvalho, Elisabete, Xochelli, Aliki, Agelink van Rentergem, Joost, Alrjoob, Waleed, Mueller, Anja, Freitas, Ana Carolina, Cocks, Kim, Creutzberg, Carien, Kyriakou, Charalampia, and van de Poll-Franse, Lonneke
- Published
- 2023
- Full Text
- View/download PDF
8. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
- Author
-
Fremond, Sarah, Andani, Sonali, Barkey Wolf, Jurriaan, Dijkstra, Jouke, Melsbach, Sinéad, Jobsen, Jan J, Brinkhuis, Mariel, Roothaan, Suzan, Jurgenliemk-Schulz, Ina, Lutgens, Ludy C H W, Nout, Remi A, van der Steen-Banasik, Elzbieta M, de Boer, Stephanie M, Powell, Melanie E, Singh, Naveena, Mileshkin, Linda R, Mackay, Helen J, Leary, Alexandra, Nijman, Hans W, Smit, Vincent T H B M, Creutzberg, Carien L, Horeweg, Nanda, Koelzer, Viktor H, and Bosse, Tjalling
- Published
- 2023
- Full Text
- View/download PDF
9. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
- Author
-
Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, Melanie E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, Hans W., Smit, Vincent T. H. B. M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, and Bosse, Tjalling
- Published
- 2022
- Full Text
- View/download PDF
10. Prediction of recurrence risk in endometrial cancer with multimodal deep learning
- Author
-
Volinsky-Fremond, Sarah, primary, Horeweg, Nanda, additional, Andani, Sonali, additional, Barkey Wolf, Jurriaan, additional, Lafarge, Maxime W., additional, de Kroon, Cor D., additional, Ørtoft, Gitte, additional, Høgdall, Estrid, additional, Dijkstra, Jouke, additional, Jobsen, Jan J., additional, Lutgens, Ludy C. H. W., additional, Powell, Melanie E., additional, Mileshkin, Linda R., additional, Mackay, Helen, additional, Leary, Alexandra, additional, Katsaros, Dionyssios, additional, Nijman, Hans W., additional, de Boer, Stephanie M., additional, Nout, Remi A., additional, de Bruyn, Marco, additional, Church, David, additional, Smit, Vincent T. H. B. M., additional, Creutzberg, Carien L., additional, Koelzer, Viktor H., additional, and Bosse, Tjalling, additional
- Published
- 2024
- Full Text
- View/download PDF
11. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
- Author
-
Horeweg, Nanda, Workel, Hagma H., Loiero, Dominik, Church, David N., Vermij, Lisa, Léon-Castillo, Alicia, Krog, Ricki T., de Boer, Stephanie M., Nout, Remi A., Powell, Melanie E., Mileshkin, Linda R., MacKay, Helen, Leary, Alexandra, Singh, Naveena, Jürgenliemk-Schulz, Ina M., Smit, Vincent T. H. B. M., Creutzberg, Carien L., Koelzer, Viktor H., Nijman, Hans W., Bosse, Tjalling, and de Bruyn, Marco
- Published
- 2022
- Full Text
- View/download PDF
12. Predictive Factors for Toxicity After Primary Chemoradiation for Locally Advanced Cervical Cancer:A Systematic Review
- Author
-
Corbeau, Anouk, Heemsbergen, Wilma D., Kuipers, Sander C., Godart, Jeremy, Creutzberg, Carien L., Nout, Remi A., de Boer, Stephanie M., Corbeau, Anouk, Heemsbergen, Wilma D., Kuipers, Sander C., Godart, Jeremy, Creutzberg, Carien L., Nout, Remi A., and de Boer, Stephanie M.
- Abstract
Purpose: Women with locally advanced cervical cancer (LACC) undergoing primary platinum-based chemoradiotherapy and brachytherapy often experience toxicities. Normal-tissue complication probability (NTCP) models quantify toxicity risk and aid in optimizing radiation therapy to minimize side effects. However, it is unclear which predictors to include in an NTCP model. The aim of this systematic review was to provide an overview of the identified predictors contributing to gastrointestinal (GI), genitourinary (GU), and vaginal toxicities and insufficiency fractures for LACC. Methods and Materials: A systematic search was performed and articles evaluating the relationship between predictors and toxicities in women with LACC treated with primary chemoradiation were included. The Quality In Prognosis Studies tool was used to assess risk of bias, with high-risk studies being excluded from further analysis. Relationships between dose-volume parameters, patient and treatment characteristics, and toxicity endpoints were analyzed. Results:Seventy-three studies were identified. Twenty-six had a low or moderate risk of bias and were therefore included. Brachytherapy-related dose-volume parameters of the GI tract, including rectum and bowel equivalent dose in 2 Gy fractions (EQD2) D2 cm3, were frequently related to toxicities, unlike GU dose-volume parameters. Furthermore, (recto)vaginal point doses predicted toxicities. Few studies evaluated external beam radiation therapy dose-volume parameters and identified rectum EQD2 V30 Gy, V40 Gy, and V55 Gy, bowel and bladder EQD2 V40 Gy as toxicity predictors. Also, total reference air kerma and vaginal reference length were associated with toxicities. Relationships between patient characteristics and GI toxicity were inconsistent. The extent of vaginal involvement at diagnosis, baseline symptoms, and obesity predicted GU or vaginal toxicities. Only 1 study evaluated
- Published
- 2024
13. Management of conjunctival melanoma with local excision and adjuvant brachytherapy
- Author
-
Brouwer, Niels J., Marinkovic, Marina, Peters, Femke P., Hulshof, Maarten C. C. M., Pieters, Bradley R., de Keizer, Rob J. W., Horeweg, Nanda, Laman, Mirjam S., Bleeker, Jaco C., van Duinen, Sjoerd G., Jager, Martine J., Creutzberg, Carien L., and Luyten, Gregorius P. M.
- Published
- 2021
- Full Text
- View/download PDF
14. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer
- Author
-
Post, Cathalijne C.B., Westermann, Anneke M., Bosse, Tjalling, Creutzberg, Carien L., and Kroep, Judith R.
- Published
- 2020
- Full Text
- View/download PDF
15. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
- Author
-
Bleiker, Eveline, Bliem, Brigitte, Chie, Weichu, Creutzberg, Carien, Deville, Valerie, Duhoux, Francois, Eilf, Kirsten, Hartup, Sue, Koller, Michael, Nagele, Eva, Nicolatou-Galitis, Ourania, Oberguggenberger, Anne, Schmalz, Claudia, Winters, Zoe, Bjelic-Radisic, V., Cardoso, F., Cameron, D., Brain, E., Kuljanic, K., da Costa, R.A., Conroy, T., Inwald, E.C., Serpentini, S., Pinto, M., Weis, J., Morag, O., Lindviksmoen Astrup, G., Tomaszweksi, K.A., Pogoda, K., Sinai, P., Sprangers, M., Aaronson, N., Velikova, G., Greimel, E., Arraras, J., and Bottomley, A.
- Published
- 2020
- Full Text
- View/download PDF
16. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
- Author
-
Tong, Thaïs M. L., primary, Bastiaannet, Esther, additional, Speetjens, Frank M., additional, Blank, Christian U., additional, Luyten, Gregorius P. M., additional, Jager, Martine J., additional, Marinkovic, Marina, additional, Vu, T. H. Khanh, additional, Rasch, Coen R. N., additional, Creutzberg, Carien L., additional, Beenakker, Jan-Willem M., additional, Hartgrink, Henk H., additional, Bosch, Jacobus J. J., additional, Kiliç, Emine, additional, Naus, Nicole C., additional, Yavuzyigitoglu, Serdar, additional, van Rij, Caroline M., additional, Burgmans, Mark C., additional, and Kapiteijn, Ellen H. W., additional
- Published
- 2023
- Full Text
- View/download PDF
17. A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial
- Author
-
Suvaal, Isabelle, Hummel, Susanna B., Mens, Jan-Willem M., van Doorn, Helena C., van den Hout, Wilbert B., Creutzberg, Carien L., and ter Kuile, Moniek M.
- Published
- 2021
- Full Text
- View/download PDF
18. Accuracy, repeatability, and reproducibility of water-fat magnetic resonance imaging in a phantom and healthy volunteer
- Author
-
Corbeau, Anouk, van Gastel, Pien, Wielopolski, Piotr A., de Jong, Nick, Creutzberg, Carien L., van der Heide, Uulke A., de Boer, Stephanie M., and Astreinidou, Eleftheria
- Published
- 2024
- Full Text
- View/download PDF
19. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative
- Author
-
Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra
- Published
- 2018
- Full Text
- View/download PDF
20. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas
- Author
-
Jamieson, Amy, primary, Vermij, Lisa, additional, Kramer, Claire J.H., additional, Jobsen, Jan J., additional, Jürgenliemk-Schulz, Ina, additional, Lutgens, Ludy, additional, Mens, Jan Willem, additional, Haverkort, Marie A.D., additional, Slot, Annerie, additional, Nout, Remi A., additional, Oosting, Jan, additional, Carlson, Joseph, additional, Howitt, Brooke E., additional, Ip, Philip P.C., additional, Lax, Sigurd F., additional, McCluggage, W. Glenn, additional, Singh, Naveena, additional, McAlpine, Jessica N., additional, Creutzberg, Carien L., additional, Horeweg, Nanda, additional, Gilks, C. Blake, additional, and Bosse, Tjalling, additional
- Published
- 2023
- Full Text
- View/download PDF
21. P1683: THE EORTC QLQ-HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE-SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA
- Author
-
Oerlemans, Simone, primary, Efficace, Fabio, additional, Shamieh, Omar, additional, Borges, Fabio Cardoso, additional, Jong, Corine De, additional, Dong, Dong, additional, Lehmann, Jens, additional, Malak, Sandra, additional, Petranovic, Duska, additional, Scholz, Christian, additional, Caocci, Giovanni, additional, Molica, Stefano, additional, Griskevicius, Laimonas, additional, Nagele, Eva, additional, Bredart, Anne, additional, Carvalho, Elisabete, additional, Xochelli, Aliki, additional, Rentergem, Joost Agelink van, additional, Alrjoob, Waleed, additional, Mueller, Anja, additional, Freitas, Ana Carolina, additional, Cocks, Kim, additional, Creutzberg, Carien, additional, Kyriakou, Charalampia, additional, and Van de Poll-Franse, Lonneke, additional
- Published
- 2023
- Full Text
- View/download PDF
22. QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
- Author
-
Van den Heerik, Anne Sophie V.M., primary, Ter Haar, Natalja T., additional, Vermij, Lisa, additional, Jobsen, Jan J., additional, Brinkhuis, Mariel, additional, Roothaan, Suzan M., additional, Leon-Castillo, Alicia, additional, Ortoft, Gitte, additional, Hogdall, Estrid, additional, Hogdall, Claus, additional, Van Wezel, Tom, additional, Lutgens, Ludy C.H.W., additional, Haverkort, Marie A.D., additional, Khattra, Jas, additional, McAlpine, Jessica N., additional, Creutzberg, Carien L., additional, Smit, Vincent T.H.B.M., additional, Gilks, C. Blake, additional, Horeweg, Nanda, additional, and Bosse, Tjalling, additional
- Published
- 2023
- Full Text
- View/download PDF
23. Abstract 5695: Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides
- Author
-
Fremond, Sarah, primary, Andani, Sonali, additional, Wolf, Jurriaan Barkey, additional, Ørtoft, Gitte, additional, Høgdall, Estrid, additional, Dijkstra, Jouke, additional, Jobsen, Jan J., additional, Jürgenliemk-Schulz, Ina M., additional, Lutgens, Ludy CHW, additional, Powell, Melanie E., additional, Singh, Naveena, additional, Mileshkin, Linda R., additional, Mackay, Helen J., additional, Leary, Alexandra, additional, Katsaros, Dionyssios, additional, Nijman, Hans W., additional, de Boer, Stephanie M., additional, Nout, Remi A., additional, Smit, Vincent T.H.B.M, additional, Creutzberg, Carien L., additional, Horeweg, Nanda, additional, Koelzer, Viktor H., additional, and Bosse, Tjalling, additional
- Published
- 2023
- Full Text
- View/download PDF
24. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)
- Author
-
Oerlemans, S., Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana carolina, Shamieh, Omar, Creutzberg, Carien l., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian w., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien m., Agelink van rentergem, Joost a., Alrjoub, Waleed, Mueller, Anja, Gomes da silva, Maria, Alves da costa, Filipa, Malak, Sandra, Cocks, Kim, Van de Poll‐Franse, L.V., Oerlemans, S., Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana carolina, Shamieh, Omar, Creutzberg, Carien l., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian w., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien m., Agelink van rentergem, Joost a., Alrjoub, Waleed, Mueller, Anja, Gomes da silva, Maria, Alves da costa, Filipa, Malak, Sandra, Cocks, Kim, and Van de Poll‐Franse, L.V.
- Abstract
Background Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high-grade (HG)- and low-grade (LG)-NHL: the EORTC QLQ-NHL-HG29 and the EORTC QLQ-NHL-LG20 to supplement the core questionnaire (EORTC QLQ-C30). Methods Overall, 768 patients with HG-NHL (N = 423) and LG-NHL (N = 345) from 12 countries completed the QLQ-C30, QLQ-NHL-HG29/QLQ-NHL-LG20 and a debriefing questionnaire at baseline, and a subset at follow-up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49). Results Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ-NHL-HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/functioning [WH]), and of the 20 items of the QLQ-NHL-LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test-retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results of both measures. A total of 31%-78% of patients with HG-NHL and 22%-73% of patients with LG-NHL reported symptoms and/or worries (e.g., tingling in hands/feet, lack of energy, and worries about recurrence). Patients reporting symptoms/worries had substantially lower HRQOL compared to those without. Discussion The use of the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision-making. Plain language summary The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires. These questionnaires measure health-related quality
- Published
- 2023
25. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27
- Author
-
Oerlemans, S., Efficace, F., Shamieh, O., Cardoso borges, F., de Jong, C., Dong, Dong, Lehmann, Jens, Malak, Sandra, Petranovic, Duska, Scholz, Christian w., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Nagele, Eva, Bredart, Anne, Carvalho, Elisabete, Xochelli, Aliki, Agelink van rentergem, Joost, Alrjoob, Waleed, Mueller, Anja, Freitas, Ana carolina, Cocks, Kim, Creutzberg, Carien, Kyriakou, Charalampia, van de Poll-Franse, L.V., Oerlemans, S., Efficace, F., Shamieh, O., Cardoso borges, F., de Jong, C., Dong, Dong, Lehmann, Jens, Malak, Sandra, Petranovic, Duska, Scholz, Christian w., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Nagele, Eva, Bredart, Anne, Carvalho, Elisabete, Xochelli, Aliki, Agelink van rentergem, Joost, Alrjoob, Waleed, Mueller, Anja, Freitas, Ana carolina, Cocks, Kim, Creutzberg, Carien, Kyriakou, Charalampia, and van de Poll-Franse, L.V.
- Abstract
Hodgkin lymphoma (HL) has become 1 of the most curable cancers. Therefore, rigorous assessment of health-related quality of life (HRQoL) and symptom burden of these patients is essential to support informed clinical decisions. The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group previously developed the EORTC Quality of Life Questionnaire (QLQ) Hodgkin Lymphoma 27. This paper reports the final results of an international study by the EORTC group to develop a HRQoL disease-specific measure for these patients: the EORTC QLQ-HL27. Patients with a confirmed diagnosis of HL (N = 381) were enrolled from 12 countries and completed the EORTC QLQ-C30, QLQ-HL27, and a debriefing questionnaire at baseline (any time after diagnosis). A subset completed a retest (n = 126) or responsiveness-to-change analyses (RCA) second measurement (n = 98). Psychometrics were evaluated. Confirmatory factor analysis showed an acceptable fit of the 27 items of the QLQ-HL27 on its 4 scales (symptom burden, physical condition/fatigue, emotional impact, and worries about health/functioning). Test–retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results. Symptom burden and fatigue was higher among patients on treatment (with 36%-83% reporting at least a few problems) compared with those who had completed treatment (19%-61% reporting at least a few problems). Prevalence of worries about health and functioning (reporting at least some worry) was similar for patients on treatment (51%-81%) vs those who had completed treatment (52%-78%). Implementation of the EORTC QLQ-HL27 in research and clinical applications will increase sensitivity of HRQoL assessment in patients with HL. High quality data generated through use of this questionnaire are expected to facilitate clinical decision making in the HL setting.
- Published
- 2023
26. QPOLE:A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
- Author
-
Van den Heerik, Anne Sophie V.M., Ter Haar, Natalja T., Vermij, Lisa, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan M., Leon-Castillo, Alicia, Ortoft, Gitte, Hogdall, Estrid, Hogdall, Claus, Van Wezel, Tom, Lutgens, Ludy C.H.W., Haverkort, Marie A.D., Khattra, Jas, McAlpine, Jessica N., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Gilks, C. Blake, Horeweg, Nanda, Bosse, Tjalling, Van den Heerik, Anne Sophie V.M., Ter Haar, Natalja T., Vermij, Lisa, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan M., Leon-Castillo, Alicia, Ortoft, Gitte, Hogdall, Estrid, Hogdall, Claus, Van Wezel, Tom, Lutgens, Ludy C.H.W., Haverkort, Marie A.D., Khattra, Jas, McAlpine, Jessica N., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Gilks, C. Blake, Horeweg, Nanda, and Bosse, Tjalling
- Abstract
PURPOSE: Detection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expensive, relatively time-consuming, and unavailable in hospitals without specialized equipment and personnel. This may hamper the implementation of POLE-testing in clinical practice. To overcome this, we developed and validated a rapid, low-cost POLE hotspot test by a quantitative polymerase chain reaction (qPCR) assay, QPOLE. MATERIALS AND METHODS: Primer and fluorescence-labeled 5'-nuclease probe sequences of the 11 established pathogenic POLE mutations were designed. Three assays, QPOLE-frequent for the most common mutations and QPOLE-rare-1 and QPOLE-rare-2 for the rare variants, were developed and optimized using DNA extracted from formalin-fixed paraffin-embedded tumor tissues. The simplicity of the design enables POLE status assessment within 4-6 hours after DNA isolation. An interlaboratory external validation study was performed to determine the practical feasibility of this assay. RESULTS: Cutoffs for POLE wild-type, POLE-mutant, equivocal, and failed results were predefined on the basis of a subset of POLE mutants and POLE wild-types for the internal and external validation. For equivocal cases, additional DNA sequencing is recommended. Performance in 282 EC cases, of which 99 were POLE-mutated, demonstrated an overall accuracy of 98.6% (95% CI, 97.2 to 99.9), a sensitivity of 95.2% (95% CI, 90.7 to 99.8), and a specificity of 100%. After DNA sequencing of 8.8% equivocal cases, the final sensitivity and specificity were 96.0% (95% CI, 92.1 to 99.8) and 100%. External validation confirmed feasibility and accuracy. CONCLUSION: QPOLE is a qPCR assay that is a quick, simple, and reliable alternative for DNA sequencing. QPOLE detects all pathogenic variants in the exonuclease domain of the POLE gene. QPOLE will
- Published
- 2023
27. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
- Author
-
Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, Bosse, Tjalling, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J.H., Jobsen, Jan J., Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A.D., Slot, Annerie, Nout, Remi A., Oosting, Jan, Carlson, Joseph, Howitt, Brooke E., Ip, Philip P.C., Lax, Sigurd F., McCluggage, W. Glenn, Singh, Naveena, McAlpine, Jessica N., Creutzberg, Carien L., Horeweg, Nanda, Gilks, C. Blake, and Bosse, Tjalling
- Abstract
PURPOSE: The clinical significance of the p53-abnormal (p53abn) molecular subtype in stage I low-grade endometrioid endometrial carcinoma (EEC) is debated. We aimed to review pathologic and molecular characteristics, and outcomes of stage I low-grade p53abn EEC in a large international cohort. EXPERIMENTAL DESIGN: Previously diagnosed stage I p53abn EC (POLE-wild-type, mismatch repair-proficient) low-grade EEC from Canadian retrospective cohorts and PORTEC-1&2 trials were included. Pathology review was performed by six expert gynecologic pathologists blinded to p53 status. IHC profiling, next-generation sequencing, and shallow whole-genome sequencing was performed. Kaplan-Meier method was used for survival analysis. RESULTS: We identified 55 stage I p53abn low-grade EEC among 3,387 cases (2.5%). On pathology review, 17 cases (31%) were not diagnosed as low-grade EEC by any pathologists, whereas 26 cases (47%) were diagnosed as low-grade EEC by at least three pathologists. The IHC and molecular profile of the latter cases were consistent with low-grade EEC morphology (ER/PR positivity, patchy p16 expression, PIK3CA and PTEN mutations) but they also showed features of p53abn EC (TP53 mutations, many copy-number alterations). These cases had a clinically relevant risk of disease recurrence (5-year recurrence-free survival 77%), with pelvic and/or distant recurrences observed in 12% of the patients. CONCLUSIONS:A subset of p53abn EC is morphologically low-grade EEC and exhibit genomic instability. Even for stage I disease, p53abn low-grade EEC are at substantial risk of disease recurrence. These findings highlight the clinical relevance of universal p53-testing, even in low-grade EEC, to identify women at increased risk of recurrence.
- Published
- 2023
28. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
- Author
-
Tong, Thaïs M.L., Bastiaannet, Esther, Speetjens, Frank M., Blank, Christian U., Luyten, Gregorius P.M., Jager, Martine J., Marinkovic, Marina, Vu, T. H.Khanh, Rasch, Coen R.N., Creutzberg, Carien L., Beenakker, Jan Willem M., Hartgrink, Henk H., Bosch, Jacobus J.J., Kiliç, Emine, Naus, Nicole C., Yavuzyigitoglu, Serdar, van Rij, Caroline M., Burgmans, Mark C., Kapiteijn, Ellen H.W., Tong, Thaïs M.L., Bastiaannet, Esther, Speetjens, Frank M., Blank, Christian U., Luyten, Gregorius P.M., Jager, Martine J., Marinkovic, Marina, Vu, T. H.Khanh, Rasch, Coen R.N., Creutzberg, Carien L., Beenakker, Jan Willem M., Hartgrink, Henk H., Bosch, Jacobus J.J., Kiliç, Emine, Naus, Nicole C., Yavuzyigitoglu, Serdar, van Rij, Caroline M., Burgmans, Mark C., and Kapiteijn, Ellen H.W.
- Abstract
Background: Uveal melanoma (UM) is a rare intraocular tumor with a dismal prognosis once metastasized. This study provides a nationwide overview and time trends of patients diagnosed with primary UM in the Netherlands between 1989 and 2019. Methods: A retrospective population-based cohort study based on patients with primary UM from the database of the Netherlands Cancer Registry (NCR), linked with the national population registry Statistics Netherlands on inhabitants’ cause of death. Two time periods (1989–2004, 2005–2019) were compared with descriptive statistics. Kaplan–Meier and (multivariate) Cox proportional hazard models were used to assess changes over time for overall survival (OS) and cancer-specific survival (CSS). Results: In total, 5036 patients were analyzed with a median age of 64.0 years at the time of diagnosis. The number of patients increased over time. In the first (1989–2004) and second (2005–2019) period, 32% versus 54% of the patients received radiotherapy (p < 0.001). The median FU time was 13.4 years. The median OS of the first and second periods was 9.5 (95% CI 8.7–10.3) versus 11.3 years (95% CI 10.3–12.3; p < 0.001). The median CSS was 30.0 years (95% CI NA) in the first period and not reached in the second period (p = 0.008). In multivariate analysis (MVA), female gender (HR 0.85; 95% CI 0.79–0.92, p < 0.001) and radiotherapy treatment (HR 0.73; 95% CI 0.64–0.83, p < 0.001) were associated with better OS. Radiotherapy treatment (HR 0.74; 95% CI 0.61–0.90, p = 0.002) was also associated with better CSS. The period of diagnosis was not associated with OS or CSS. Conclusions: In this study of patients with primary UM, there was a shift to the diagnosis of smaller tumors, possibly due to stage migration. There was also an increase in eye-preserving treatments over time. OS and CSS were modestly improved in the second time period; however, the time per
- Published
- 2023
29. Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
- Author
-
MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, Bosse, Tjalling, MS Radiotherapie, Cancer, Jamieson, Amy, Vermij, Lisa, Kramer, Claire J H, Jobsen, Jan J, Jürgemlienk-Schulz, Ina, Lutgens, Ludy, Mens, Jan Willem, Haverkort, Marie A D, Slot, Annerie, Nout, Remi A, Oosting, Jan, Carlson, Joseph, Howitt, Brooke E, Ip, Philip P C, Lax, Sigurd F, McCluggage, W Glenn, Singh, Naveena, McAlpine, Jessica N, Creutzberg, Carien L, Horeweg, Nanda, Gilks, C Blake, and Bosse, Tjalling
- Published
- 2023
30. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts
- Author
-
MS Radiotherapie, Cancer, Fremond, Sarah, Andani, Sonali, Barkey Wolf, Jurriaan, Dijkstra, Jouke, Melsbach, Sinéad, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan, Jurgenliemk-Schulz, Ina, Lutgens, Ludy C.H.W., Nout, Remi A., van der Steen-Banasik, Elzbieta M., de Boer, Stephanie M., Powell, Melanie E., Singh, Naveena, Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Smit, Vincent T.H.B.M., Creutzberg, Carien L., Horeweg, Nanda, Koelzer, Viktor H., Bosse, Tjalling, MS Radiotherapie, Cancer, Fremond, Sarah, Andani, Sonali, Barkey Wolf, Jurriaan, Dijkstra, Jouke, Melsbach, Sinéad, Jobsen, Jan J., Brinkhuis, Mariel, Roothaan, Suzan, Jurgenliemk-Schulz, Ina, Lutgens, Ludy C.H.W., Nout, Remi A., van der Steen-Banasik, Elzbieta M., de Boer, Stephanie M., Powell, Melanie E., Singh, Naveena, Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Smit, Vincent T.H.B.M., Creutzberg, Carien L., Horeweg, Nanda, Koelzer, Viktor H., and Bosse, Tjalling
- Published
- 2023
31. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
- Author
-
Van Gool, Inge C, Stelloo, Ellen, Nout, Remi A, Nijman, Hans W, Edmondson, Richard J, Church, David N, MacKay, Helen J, Leary, Alexandra, Powell, Melanie E, Mileshkin, Linda, Creutzberg, Carien L, Smit, Vincent T H B M, and Bosse, Tjalling
- Published
- 2016
- Full Text
- View/download PDF
32. FIGO staging of endometrial cancer: 2023.
- Author
-
Berek, Jonathan S., Matias-Guiu, Xavier, Creutzberg, Carien, Fotopoulou, Christina, Gaffney, David, Kehoe, Sean, Lindemann, Kristina, Mutch, David, and Concin, Nicole
- Subjects
MICROMETASTASIS ,ENDOMETRIAL cancer ,TUMOR classification ,LYMPHATIC metastasis ,CANCER patients - Abstract
Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Results: Based on the existing evidence, the substages were defined as follows: S tage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. S tage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) nonaggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. S tage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. S tage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification ( POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut). Summary: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
- Author
-
Stelloo, Ellen, Bosse, Tjalling, Nout, Remi A, MacKay, Helen J, Church, David N, Nijman, Hans W, Leary, Alexandra, Edmondson, Richard J, Powell, Melanie E, Crosbie, Emma J, Kitchener, Henry C, Mileshkin, Linda, Pollock, Pamela M, Smit, Vincent T, and Creutzberg, Carien L
- Published
- 2015
- Full Text
- View/download PDF
34. MR‐based follow‐up after brachytherapy and proton beam therapy in uveal melanoma
- Author
-
Tang, Michael, primary, Ferreira, Teresa, additional, Jaarsma‐Coes, Myriam, additional, Klaassen, Lisa, additional, Marinkovic, Marina, additional, Vu, Khanh, additional, Rasch, Coen, additional, Creutzberg, Carien, additional, Horeweg, Nanda, additional, Klaver, Yvonne, additional, Rodrigues, Myra, additional, Luyten, Gregorius, additional, and Beenakker, Jan‐Willem, additional
- Published
- 2022
- Full Text
- View/download PDF
35. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)
- Author
-
Oerlemans, Simone, Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana Carolina, Shamieh, Omar, Creutzberg, Carien L., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Griškevičius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien M., Agelink van Rentergem, Joost A., Alrjoub, Waleed, Mueller, Anja, Gomes Da Silva, Maria, Alves da Costa, Filipa, Malak, Sandra, Cocks, Kim, and van de Poll‐Franse, Lonneke V.
- Subjects
EORTC ,non‐Hodgkin lymphoma ,PRO ,psychometric properties ,quality of life ,questionnaire ,symptoms - Abstract
Background: Health‐related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non‐Hodgkin‐lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high‐grade (HG)‐ and low‐grade (LG)‐NHL: the EORTC QLQ‐NHL‐HG29 and the EORTC QLQ‐NHL‐LG20 to supplement the core questionnaire (EORTC QLQ‐C30). Methods: Overall, 768 patients with HG‐NHL (N = 423) and LG‐NHL (N = 345) from 12 countries completed the QLQ‐C30, QLQ‐NHL‐HG29/QLQ‐NHL‐LG20 and a debriefing questionnaire at baseline, and a subset at follow‐up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49). Results: Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ‐NHL‐HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/ functioning [WH]), and of the 20 items of the QLQ‐NHL‐LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test–retest reliability, convergent validity, known‐group comparisons, and RCA find satisfactory results of both measures. A total of 31%–78% of patients with HG‐NHL and 22%–73% of patients with LG‐NHL reported symptoms and/or worries (e.g., tingling in hands/ feet, lack of energy, and worries about recurrence). Patients reporting symptoms/ worries had substantially lower HRQOL compared to those without. Discussion: The use of the EORTC QLQ‐NHL‐HG29 and QLQ‐NHL‐LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision‐making. Plain language summary � The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires. � These questionnaires measure health‐related quality of life. � The questionnaires are for patients with high‐grade or low‐grade non‐Hodgkin lymphoma. � They are called the EORTC QLQ‐NHL‐HG29 and QLQ‐NHL‐LG20. � The questionnaires are now internationally validated. � This study demonstrates that the questionnaires are reliably and valid, which are important aspects of a questionnaire. � The questionnaires can now be used in clinical trials and practice. � With the information gathered from the questionnaires, patients and clinicians can better evaluate treatments and discuss the best choice for a patient.
- Published
- 2023
36. Sexual dysfunction and infertility as late effects of cancer treatment
- Author
-
Schover, Leslie R., van der Kaaij, Marleen, van Dorst, Eleonora, Creutzberg, Carien, Huyghe, Eric, and Kiserud, Cecilie E.
- Published
- 2014
- Full Text
- View/download PDF
37. ENdometrial cancer SURvivors’ follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial
- Author
-
Ezendam, Nicole P. M., de Rooij, Belle H., Kruitwagen, Roy F. P. M., Creutzberg, Carien L., van Loon, Ingrid, Boll, Dorry, Vos, M. Caroline, and van de Poll-Franse, Lonneke V.
- Published
- 2018
- Full Text
- View/download PDF
38. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
- Author
-
Bosse, Tjalling, ter Haar, Natalja T, Seeber, Laura M, Diest, Paul J v, Hes, Frederik J, Vasen, Hans FA, Nout, Remi A, Creutzberg, Carien L, Morreau, Hans, and Smit, Vincent THBM
- Published
- 2013
- Full Text
- View/download PDF
39. Automated causal inference in application to randomized controlled clinical trials
- Author
-
Wu, Ji Q., Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., Koelzer, Viktor H., Wu, Ji Q., Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., and Koelzer, Viktor H.
- Abstract
Randomized controlled trials (RCTs) are considered the gold standard for testing causal hypotheses in the clinical domain; however, the investigation of prognostic variables of patient outcome in a hypothesized cause–effect route is not feasible using standard statistical methods. Here we propose a new automated causal inference method (AutoCI) built on the invariant causal prediction (ICP) framework for the causal reinterpretation of clinical trial data. Compared with existing methods, we show that the proposed AutoCI allows one to clearly determine the causal variables of two real-world RCTs of patients with endometrial cancer with mature outcome and extensive clinicopathological and molecular data. This is achieved via suppressing the causal probability of non-causal variables by a wide margin. In ablation studies, we further demonstrate that the assignment of causal probabilities by AutoCI remains consistent in the presence of confounders. In conclusion, these results confirm the robustness and feasibility of AutoCI for future applications in real-world clinical analysis.
- Published
- 2022
40. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
- Author
-
Leon-Castillo, Alicia, Horeweg, Nanda, Peters, Elke E.M., Rutten, Tessa, ter Haar, Natalja, Smit, Vincent T.H.B.M., Kroon, Cor D., Boennelycke, Marie, Hogdall, Estrid, Hogdall, Claus, Nout, Remi R.A., Creutzberg, Carien L., Ortoft, Gitte, Bosse, Tjalling, Leon-Castillo, Alicia, Horeweg, Nanda, Peters, Elke E.M., Rutten, Tessa, ter Haar, Natalja, Smit, Vincent T.H.B.M., Kroon, Cor D., Boennelycke, Marie, Hogdall, Estrid, Hogdall, Claus, Nout, Remi R.A., Creutzberg, Carien L., Ortoft, Gitte, and Bosse, Tjalling
- Abstract
Introduction: The clinical role of the molecular endometrial cancer (EC) classification has not been fully explored in patients staged with lymphadenectomy or without adjuvant treatment, conditions that could potentially moderate the prognostic value of the classification. We aimed to evaluate the clinical outcome of the molecular subgroups in patients with high-grade EC staged by lymphadenectomy and those without adjuvant treatment. Methods: DNA-sequencing for the detection of pathogenic POLE-exonuclease domain mutations and immunohistochemistry for mismatch repair (MMR) proteins and p53 expression were performed on 412 high-grade EC from the Danish Gynaecological Cancer Database (2005–2012) to classify them as POLE-ultramutated (POLEmut), MMR-deficient (MMRd), p53-mutant (p53abn), or no specific molecular profile (NSMP). Patients with stage IV or residual disease after surgery were excluded. Kaplan-Meier method, log-rank test and Cox proportional hazard models were used for analysis. Results: Molecular analysis was successful in 367 EC; 251 patients had undergone lymphadenectomy. Five-year recurrence rates in this subgroup of patients was 36.7% for women with p53abn EC, 0.0% for POLEmut EC, 13.4% for MMRd EC and 42.9% for NSMP EC (p < 0.001). Similar results were observed among stage IA-IB patients. Among patients without adjuvant treatment (n = 264), none with POLEmut EC (n = 26) had a recurrence. Conclusion: The molecular EC classification has strong prognostic value, independent of clinicopathological factors, also among high-grade EC patients staged by lymphadenectomy and those without adjuvant treatment. The unfavourable prognosis of early-stage p53abn EC is not due to undetected lymph node metastasis, and the indolent behaviour of POLEmut EC is independent of adjuvant treatment.
- Published
- 2022
41. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer
- Author
-
Peters, Elke E.M., León-Castillo, Alicia, Smit, Vincent T.H.B.M., Boennelycke, Marie, Hogdall, Estrid, Hogdall, Claus, Creutzberg, Carien, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Mens, Jan Willem M., Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Ortoft, Gitte, Bosse, Tjalling, Nout, Remi, Peters, Elke E.M., León-Castillo, Alicia, Smit, Vincent T.H.B.M., Boennelycke, Marie, Hogdall, Estrid, Hogdall, Claus, Creutzberg, Carien, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Mens, Jan Willem M., Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Ortoft, Gitte, Bosse, Tjalling, and Nout, Remi
- Abstract
Lymphovascular space invasion (LVSI) occurs in a minority of endometrial cancer (EC) cases, and the extent of LVSI is an important risk factor for recurrence and/or metastases. Our aim was to improve the reproducibility of measuring clinically meaningful LVSI by performing a quantitative analysis of the correlation between LVSI and the risk of pelvic lymph node recurrence in EC. EC samples from PORTEC-1 and PORTEC-2 trials were retrieved and used to collect quantitative data, including the number of LVSI-positive vessels per H&E-stained slide. Using a predefined threshold for clinical relevance, the risk of pelvic lymph node recurrence risk was calculated (Kaplan-Meier method, with Cox regression) using a stepwise adjustment for the number of LVSI-positive vessels. This analysis was then repeated in the Danish Gynecological Cancer Database (DGCD) cohort. Among patients in PORTEC-1 and PORTEC-2 trials who did not receive external beam radiotherapy, the 5-yr pelvic lymph node recurrence risk was 3.3%, 6.7% (P=0.51), and 26.3% (P<0.001), respectively when 0, 1 to 3, or ≥4 vessels had LVSI involvement; similar results were obtained for the DGCD cohort. Furthermore, both the average number of tumor cells in the largest embolus and the number of LVSI-positive H&E slides differed significantly between focal LVSI and substantial LVSI. On the basis of these results, we propose a numeric threshold (≥4 LVSI-involved vessels in at least one H&E slide) for defining clinically relevant LVSI in EC, thereby adding supportive data to the semiquantitative approach. This will help guide gynecologic pathologists to differentiate between focal and substantial LVSI, especially in borderline cases.
- Published
- 2022
42. Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-Risk Endometrial Cancer
- Author
-
Peters, Elke E.M., Léon-Castillo, Alicia, Hogdall, Estrid, Boennelycke, Marie, Smit, Vincent T.H.B.M., Hogdall, Claus, Creutzberg, Carien L., Bosse, Tjalling, Nout, Remi A., Ørtoft, Gitte, Peters, Elke E.M., Léon-Castillo, Alicia, Hogdall, Estrid, Boennelycke, Marie, Smit, Vincent T.H.B.M., Hogdall, Claus, Creutzberg, Carien L., Bosse, Tjalling, Nout, Remi A., and Ørtoft, Gitte
- Abstract
Approximately 15% of patients with endometrial cancer present with high-risk disease (HREC). Moreover, assessing the extent of lymphovascular space invasion (LVSI) may provide prognostic insight among patients with HREC. The aim of this study was to determine whether the extent of LVSI can serve as a prognostic factor in HREC. All cases of ESMO-ESGO-ESTRO 2016 classified HREC in the Danish Gynecological Cancer Database (DGCD) diagnosed from 2005 to 2012 were reviewed for the presence and extent of LVSI (categorized using a 3-tiered definition). We used the Kaplan-Meier analysis to calculate actuarial survival rates, both adjusted and unadjusted Cox regression analyses were used to calculate the proportional hazard ratio (HR). A total of 376 patients were included in our analysis. Among 305 patients with stage I/II HREC, 8.2% and 6.2% had focal or substantial LVSI, respectively, compared with 12.7% and 38.0% of 71 patients with stage III/IV HREC, respectively. Moreover, the estimated 5-yr recurrence-free survival rate was significantly lower among patients with substantial LVSI compared with patients with no LVSI for both stage I/II (HR: 2.8; P=0.011) and stage III/IV (HR: 2.9; P=0.003) patients. Similarly, overall survival was significantly lower among patients with substantial LVSI for both stage I/II (HR: 3.1; P<0.001) and stage III/IV (HR: 3.2; P=0.020) patients. In patients with HREC, substantial LVSI is an independent adverse prognostic factor for lymph node and distant metastases, leading to reduced survival. Thus, the extent of LVSI should be incorporated into routine pathology reports in order to guide the appropriate choice of adjuvant treatment.
- Published
- 2022
43. p53 immunohistochemistry in endometrial cancer:clinical and molecular correlates in the PORTEC-3 trial
- Author
-
Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, M. E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, H. W., Smit, V. T.H.B.M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling, de Boer, S. M., Creutzberg, C. L., Bosse, T., Kroep, J., Nout, R. A., de Bruyn, M., Singh, N., Kitchener, H. C., Crosbie, E., Edmondson, R., Church, D. N., Leary, A., Mileshkin, L., Pollock, P. M., MacKay, H., Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, M. E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, H. W., Smit, V. T.H.B.M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, Bosse, Tjalling, de Boer, S. M., Creutzberg, C. L., Bosse, T., Kroep, J., Nout, R. A., de Bruyn, M., Singh, N., Kitchener, H. C., Crosbie, E., Edmondson, R., Church, D. N., Leary, A., Mileshkin, L., Pollock, P. M., and MacKay, H.
- Abstract
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and show abnormal immunohistochemical (IHC) staining for p53. Correct interpretation of routinely performed p53 IHC has therefore become of paramount importance. We aimed to comprehensively investigate abnormal p53 IHC patterns and their relation to clinicopathological and molecular features. Tumor material of 411 molecularly classified high-risk EC from consenting patients from the PORTEC-3 clinical trial were collected. p53 IHC was successful in 408 EC and was considered abnormal when the tumor showed a mutant expression pattern (including subclonal): overexpression, null or cytoplasmic. The presence of pathogenic mutations was determined by next generation sequencing (NGS). Abnormal p53 expression was observed in 131/408 (32%) tumors. The most common abnormal p53 IHC pattern was overexpression (n = 89, 68%), followed by null (n = 12, 9%) and cytoplasmic (n = 3, 2%). Subclonal abnormal p53 staining was observed in 27 cases (21%), which was frequently but not exclusively, associated with POLE mutations and/or MMRd (n = 22/27; p < 0.001). Agreement between p53 IHC and TP53 NGS was observed in 90.7%, resulting in a sensitivity and specificity of 83.6% and 94.3%, respectively. Excluding POLEmut and MMRd EC, as per the WHO-endorsed algorithm, increased the accuracy to 94.5% with sensitivity and specificity of 95.0% and 94.1%, respectively. Our data shows that awareness of the abnormal p53 IHC patterns are prerequisites for correct EC molecular classification. Subclonal abnormal p53 expression is a strong indicator for POLEmut and/or MMRd EC. No significant differences in clinical outcomes were observed among the abnormal p53 IHC patterns. Our data support use of the WHO-endo
- Published
- 2022
44. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial:Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy
- Author
-
Wortman, Bastiaan G., Post, Cathalijne C. B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jurgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Helene, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C. H. W., Kitchener, Henry C., Brooks, Susan, Nijman, Hans W., Astreinidou, Eleftheria, Putter, Hein, Creutzberg, Carien L., de Boer, Stephanie M., Wortman, Bastiaan G., Post, Cathalijne C. B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jurgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Helene, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C. H. W., Kitchener, Henry C., Brooks, Susan, Nijman, Hans W., Astreinidou, Eleftheria, Putter, Hein, Creutzberg, Carien L., and de Boer, Stephanie M.
- Abstract
Purpose: Radiation therapy techniques have developed from 3-dimensional conformal radiation therapy (3DCRT) to intensity modulated radiation therapy (IMRT), with better sparing of the surrounding normal tissues. The current analysis aimed to investigate whether IMRT, compared to 3DCRT, resulted in fewer adverse events (AEs) and patient-reported symptoms in the randomized PORTEC-3 trial for high-risk endometrial cancer. Methods and Materials: Data on AEs and patient-reported quality of life (QoL) of the PORTEC-3 trial were available for analysis. Physician-reported AEs were graded using Common Terminology Criteria for Adverse Events v3.0. QoL was assessed by the European Organisation for Research and Treatment of Cancer QLQC30, CX24, and OV28 questionnaires. Data were compared between 3DCRT and IMRT. A P value of ≤ .01 was considered statistically significant due to the risk of multiple testing. For QoL, combined scores 1 to 2 (“not at all” and “a little”) versus 3 to 4 (“quite a bit” and “very much”) were compared between the techniques. Results: Of 658 evaluable patients, 559 received 3DCRT and 99 IMRT. Median follow-up was 74.6 months. During treatment no significant differences were observed, with a trend for more grade ≥3 AEs, mostly hematologic and gastrointestinal, after 3DCRT (37.7% vs 26.3%, P = .03). During follow-up, 15.4% (vs 4%) had grade ≥2 diarrhea, and 26.1% (vs 13.1%) had grade ≥2 hematologic AEs after 3DCRT (vs IMRT) (both P < .01). Among 574 (87%) patients evaluable for QoL, 494 received 3DCRT and 80 IMRT. During treatment, 37.5% (vs 28.6%) reported diarrhea after 3DCRT (vs IMRT) (P = .125); 22.1% (versus 10.0%) bowel urgency (P = 0039), and 18.2% and 8.6% abdominal cramps (P = .058). Other QoL scores showed no differences. Conclusions: IMRT resulted in fewer grade ≥3 AEs during treatment and significantly lower rates of grade ≥2 diarrhea and hematologic AEs during follow-up. Trends toward fewer patient-reported bowel urgency and abdominal cr
- Published
- 2022
45. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer
- Author
-
MS Radiotherapie, Cancer, Peters, Elke E.M., León-Castillo, Alicia, Smit, Vincent T.H.B.M., Boennelycke, Marie, Hogdall, Estrid, Hogdall, Claus, Creutzberg, Carien, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Mens, Jan Willem M., Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Ortoft, Gitte, Bosse, Tjalling, Nout, Remi, MS Radiotherapie, Cancer, Peters, Elke E.M., León-Castillo, Alicia, Smit, Vincent T.H.B.M., Boennelycke, Marie, Hogdall, Estrid, Hogdall, Claus, Creutzberg, Carien, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Mens, Jan Willem M., Lutgens, Ludy C.H.W., Van Der Steen-Banasik, Elzbieta M., Ortoft, Gitte, Bosse, Tjalling, and Nout, Remi
- Published
- 2022
46. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy
- Author
-
MS Radiotherapie, Cancer, Wortman, Bastiaan G., Post, Cathalijne C.B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Hélène, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C.H.W., Kitchener, Henry C., Brooks, Susan, Nijman, Hans W., Astreinidou, Eleftheria, Putter, Hein, Creutzberg, Carien L., de Boer, Stephanie M., MS Radiotherapie, Cancer, Wortman, Bastiaan G., Post, Cathalijne C.B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Hélène, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C.H.W., Kitchener, Henry C., Brooks, Susan, Nijman, Hans W., Astreinidou, Eleftheria, Putter, Hein, Creutzberg, Carien L., and de Boer, Stephanie M.
- Published
- 2022
47. Automated causal inference in application to randomized controlled clinical trials
- Author
-
MS Radiotherapie, Cancer, Wu, Ji Q., Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., Koelzer, Viktor H., MS Radiotherapie, Cancer, Wu, Ji Q., Horeweg, Nanda, de Bruyn, Marco, Nout, Remi A., Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Jobsen, Jan J., van der Steen-Banasik, Elzbieta M., Nijman, Hans W., Smit, Vincent T.H.B.M., Bosse, Tjalling, Creutzberg, Carien L., and Koelzer, Viktor H.
- Published
- 2022
48. Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
- Author
-
Church, David N., Stelloo, Ellen, Nout, Remi A., Valtcheva, Nadejda, Depreeuw, Jeroen, ter Haar, Natalja, Noske, Aurelia, Amant, Frederic, Tomlinson, Ian P. M., Wild, Peter J., Lambrechts, Diether, Jürgenliemk-Schulz, Ina M., Jobsen, Jan J., Smit, Vincent T. H. B. M., Creutzberg, Carien L., and Bosse, Tjalling
- Published
- 2015
- Full Text
- View/download PDF
49. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
- Author
-
Corbeau, Anouk, primary, Nout, Remi A., additional, Mens, Jan Willem M., additional, Horeweg, Nanda, additional, Godart, Jérémy, additional, Kerkhof, Ellen M., additional, Kuipers, Sander C., additional, van Poelgeest, Mariette I. E., additional, Kroep, Judith R., additional, Boere, Ingrid A., additional, van Doorn, Helena C., additional, Hoogeman, Mischa S., additional, van der Heide, Uulke A., additional, Putter, Hein, additional, Welters, Marij J. P., additional, van der Burg, Sjoerd H., additional, Creutzberg, Carien L., additional, and de Boer, Stephanie M., additional
- Published
- 2021
- Full Text
- View/download PDF
50. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making
- Author
-
Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jurgenliemk-Schulz, Ina M., Snyers, A., Stiggelbout, Anne M., Creutzberg, Carien L., Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jurgenliemk-Schulz, Ina M., Snyers, A., Stiggelbout, Anne M., and Creutzberg, Carien L.
- Abstract
Item does not contain fulltext
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.